Pay in 4 interest-free payments of $26.25 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Formula: C28H30N6O3
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
01-10 μM) blocks CK1ϵ-mediated PER3 nuclear localization mediated by CK1ϵ and suppresses PER2 degradation at 1 μM
Heclin does not block E2 binding but causes a conformational change that results in oxidation of the active site Cys
GS-5885 diacetone
Ruxolitinib (S) 05 trifluoroacetate Formula: C28H30N6O3S Ruxolitinib is a less active enantiomer of Ruxolitinib, a JAK1 2 inhibitor. S Ruxolitinib was initially developed to target the constitutive activation of the JAK STAT pathway. Janus kinases (JAKs) are a family of cytoplasmic tyrosine kinases that mediates signals from the receptors for various cytokines and growth factors that have a key role in haematopoiesis and immune function. Ruxolitinib maintains its anti JAK activity by competitive
US$ 98.00
US$ 213.00